2269:TSEMeiji Holdings Co., Ltd. Analysis

OliX Pharmaceuticals is trading at 117,000 KRW, well below its 20‑day SMA (151,970), 50‑day SMA (163,604) and 200‑day SMA (134,468), indicating a bearish price environment. The RSI of 33.4 suggests the stock is oversold, yet the MACD line sits beneath its signal with a negative histogram, reinforcing a bearish momentum. Price is hovering just above the identified support level of 112,000 KRW and far from the resistance at 188,500 KRW, while a 30‑day volatility of nearly 98% and a beta of 1.34 point to heightened price swings. Historical max drawdown of -43% further underscores the downside risk.
Fundamentally, the company reports zero earnings per share, a negative operating margin of -3% and an astronomical price‑to‑sales ratio of 17,304, signaling severe overvaluation. Despite a sizable cash pile of 108 B KRW, debt stands at 21.8 B KRW** with a debt‑to‑equity ratio of 14.99, exposing financial strain. The biotech sector’s pipeline potential is offset by high regulatory uncertainty and a lack of dividend income, making the stock’s risk profile steep.